Board of Directors - Officers

Mr. Hastings brings more than 20 years of experience as a biotechnology and pharmaceutical industry executive. He has served as President and CEO of OncoMed Pharmaceuticals since January 2006. Prior to joining OncoMed, Mr. Hastings was President and Chief Executive Officer of QLT, Inc. Previous to that, Mr. Hastings served as President and Chief Executive Officer of Axys Pharmaceuticals, which was acquired by Celera Corporation in 2001. From 1999 to 2001, Mr. Hastings served as the President of Chiron BioPharmaceuticals, a division of Chiron Corporation. Prior to that, he was President and Chief Executive Officer of LXR Biotechnology. Mr. Hastings also held a series of management positions of increasing responsibility at Genzyme Corporation, including serving as President of Genzyme Therapeutics Europe as well as President of Worldwide Therapeutics. Mr. Hastings also served as Vice President, Marketing and Sales and General Manager, Europe for Synergen, Inc., and previously held a series of marketing and sales management positions with Hoffmann-La Roche. Mr Hastings was recently Chairman of the Board of Proteolix (sold to Onyx Pharmaceuticals in 2009), and served on the boards of ViaCell (sold to Perkin-Elmer in 2008), and Cerimon Pharmaceuticals. He is currently Chairman of the Board of the Bay Area Biosciences Association (Bay Bio) and serves on the executive committee of the board of directors of the Biotechnology Industry Association. He received a Bachelor of Science degree in pharmacy from the University of Rhode Island.

Dr. Molineaux co-founded Proteolix in December 2003 and served as the Company’s Chief Scientific Officer.  From January 2006 until February 2009, she served as the Company’s Chief Executive Officer, at which time she transitioned back to the role of CSO with responsibility for all research, development and clinical affairs activities. Prior to joining Proteolix, Dr. Molineaux was Vice President, Biology at Rigel Pharmaceuticals from 2000 to 2003. Before that, she was Vice President, Biology at Praelux, and from 1994 through 1999, Dr. Molineaux served as Vice President of Drug Development at Praecis Pharmaceuticals. From 1989 until 1994 she was a scientist in the Immunology group at Merck, in Rahway, NJ. Dr. Molineaux received a B.S. in Biology from Smith College, a Ph.D. in Molecular Biology from Johns Hopkins University, and completed a postdoctoral fellowship at Columbia University.

John Melo has more than 20 years of combined experience as a business leader and expert in the global fuels industry. Before joining Amyris, Mr. Melo was President of U.S. fuels operations for British Petroleum, where he successfully led programs to increase marketing volumes, reduce costs, and significantly improve financial returns. During his eight years with BP, Mr. Melo also served as Chief Information Officer of the refining and marketing segment; Senior Advisor for e-business strategy to Lord Browne, BP group chief executive; and Director of global brand development. In this last role, he helped develop the “Helios” re-branding effort. Before joining BP, Mr. Melo was with Ernst & Young and a member of the management teams for several startup companies, including Computer Aided Services and Alldata Corporation.

Scott is a fourth generation San Franciscan, a U.C. Berkeley graduate, a Certified Public Accountant, and has provided business advisory and audit services to Bay Area technology companies since 1980.

He co-authored E&Y's Biotech 2000 "Convergence," Biotech 99 "Bridging the Gap," and Biotech 98 "New Directions;" and served on the Advisory Council of the U.C. Entrepreneurs' Forum.

Scott has extensive experience with both public and private financings including venture financings and initial and follow-on offerings (both debt and equity); has worked on over $5 billion dollars of M&A transactions and is considered a recognized expert in the M&A arena including both poolings and purchase transactions; and his clients include a large number of our local biotechnology companies.

Bruce W. Jenett is a partner of, and Co-Chair of the Global Life Sciences Sector of, DLA Piper LLP (US), resident in the firm's East Palo Alto, California office. Mr. Jenett's practice is focused on the representation of U.S. and international business and finance clients in the life sciences industry. He is highly experienced in equity and debt financing, licensing and distribution, strategic alliances, joint ventures, and mergers and acquisitions, as well as general counseling issues, representing both start-ups and large multinational corporations. Mr. Jenett has, for example, represented clients in one of the largest (in financial terms) ag-bio partnering deals in history, and one of the largest (also in financial terms) partnering deals done by an Irish venture capital-backed biotechnology company with a major pharmaceutical company.

Mr. Jenett is a frequent speaker on corporate and finance issues to both business and attorney audiences. He is a member of the Bioethics Committee of BIO (the Biotechnology Industry Organization), and of the Board of Directors of BayBio, and is a member of, and is Co-Chair of the Strategic Planning Committee of, San Francisco Mayor Gavin Newsom's Biotech Advisory Council.

Mr. Jenett also is named consistently as one of the leading business lawyers in the United States by Chambers & Partners, and as a leading biotechnology industry lawyer in “Best Lawyers In America” for 2007, 2008 and 2009, is on the Law & Politics “Super Lawyers” list for Northern California for corporate and securities law for 2007, 2008 and 2009, and is listed in The International Who's Who of Life Sciences Lawyers 2008, and in the San Francisco Business Times “2009 “Best Lawyers in The Bay Area” and “Best Biotechnology Lawyers”.

Mr. Jenett is a graduate of Princeton University, and holds a J.D. from Georgetown University Law Center. He is a member of State Bar of California and of the State Bar of New York.

Gregg Alton is Senior Vice President and General Counsel for Gilead Sciences, Inc. Mr. Alton joined Gilead in 1999 and is currently responsible for legal affairs, government affairs and health policy and Gilead’s access program. Prior to joining Gilead, Mr. Alton was an attorney at the law firm of Cooley Godward LLP where he focused on mergers and acquisitions, corporate partnership and corporate finance transactions for healthcare and information technology companies.

Mr. Alton is a member of the board and treasurer of the AIDS Healthcare Foundation. He received his J.D. from Stanford Law School and his bachelor’s degree from the University of California at Berkeley.

Mr. Michael V. Arbige, Ph.D., is senior vice president, technology, for Genencor International. Since joining Genencor International in 1990, he has served as vice president of research, vice president of development, senior scientist and director of fermentation and recovery.

He received his Bachelor of Science degree in Microbiology from the University of Rhode Island in 1977 and then his Ph.D. in the field of Microbial Physiology (1982) from the University of New Hampshire. It was at the University of New Hampshire where Mr. Arbige specialized in prokaryotic genetic stability, microbial growth, and advanced fermentation systems.

After a brief period at the Environmental Protection Agency, Mr. Arbige joined the Genencor Incorporated startup venture as one of its' first employees in 1982. During his early tenure at Genencor Incorporated, Mr. Arbige was the fermentation leader in the development of the first series of recombinant and protein engineered largescale protein products ever delivered to the marketplace.

Dr. Charles Baum is Senior Vice President for Biotechnology Unit and Oncology Clinical Research within Pfizer’s Worldwide Research & Development division. His responsibilities include clinical trial planning, execution, and oversight of the biologics and therapeutic vaccine clinical portfolio. Dr. Baum has worked at Pfizer since 2003, serving in roles of increasing responsibility including as Vice President and Head of Oncology Development and as Chief Medical Officer for Pfizer’s Biotherapeutics and Bioinnovation Center. He was responsible for the development of the oncology portfolio, including Axitinib, Crizotinib and the approval of Sutent® (sunitinib) for the treatment of gastrointestinal stromal tumor (GIST) and renal cell carcinoma.

Prior to joining Pfizer, Dr. Baum was responsible for the Phase I-IV development of several oncology compounds at Schering-Plough, including the development of temozolomide which was approved for the treatment of patients with advanced brain tumors. His career has included academic and hospital positions at Stanford and Emory universities, as well as positions of increasing responsibility within the pharmaceutical industry (Systemix, Searle, and Schering-Plough).

Dr. Baum is a medical doctor and scientist having received his M.D. and Ph.D. (Immunology) from Washington University School of Medicine in St. Louis, Missouri. He did his post-graduate work at Stanford University in Palo Alto, California, where he also completed his medical residency and conducted research on human bone marrow stem cells with Dr. Irving Weissman. Dr. Baum has received research grants from the National Institutes of Health and the American Cancer Society, published more than 50 peer-reviewed manuscripts, and holds a number of patents and patent applications.

Laura A. Brege is the former Chief Operating Officer at Onyx Pharmaceuticals, Inc. In that role, she was responsible for the sales and marketing, medical affairs, legal, and compliance functions. Before joining Onyx, Ms. Brege was a general partner at Red Rock Management, a venture capital firm. Prior to Red Rock, she was the Senior Vice President and Chief Financial Officer at COR Therapeutics. Earlier in her career, Ms. Brege served as Vice President and Chief Financial Officer at Flextronics and Vice President and Treasurer of The Cooper Companies. Ms. Brege earned her undergraduate degree from Ohio University and has an MBA from the University of Chicago. Ms. Brege serves on the boards of Angiotech Pharmaceuticals, Inc., ACADIA Pharmaceuticals and The Ohio University Foundation.

Peter Daly is a senior vice president in our technology division at Wells Fargo Insurance Services. He provides direction for a team of risk management and insurance professionals who deliver brokerage services to customers.

He started in the insurance industry in 1980 as a commercial lines marketing representative for the CNA Insurance Companies. Since the early 1980’s he has worked with many cutting edge customers.  Throughout Peter’s career, he has emerged in the technology business and in the special needs market segment. His experience with companies that outsourced operations led him to develop Risk Insurance programs to protect their supply chain exposures, particularly for the semiconductor and life science industries.

Peter has also published articles on a variety of topics including risk management for outsourced life science companies and the insurance pricing cycles.

Peter graduated from Princeton University in 1976, where he was an All American swimmer. A life long student, Peter earned his Certified Insurance Counselor designation in 1989 and has completed CPCU and CRM courses.

Active in community service, Peter has been chairperson of the Woodside Recreation Committee, co-chair of the search committee for a new superintendent for Woodside School and board member of the Lighthouse for the Blind and Visually Impaired. He is currently a member of the Chapter Board for the Northern California/Northern Nevada Alzheimer’s Association and BayBio’s Board of Directors. Peter currently lives in Woodside California with his wife, where they have raised their four children.

Gordon K. Davidson is a partner in the Corporate Group and Chairman of Fenwick & West LLP. Mr. Davidson advises high technology companies, clean technology and life sciences companies. Mr. Davidson’s clients range from startups to Fortune 1000 companies. He has worked on over 30 public offerings and has represented boards of directors, audit committees and executives in numerous special investigations.

Mr. Davidson also advises venture capital investors and investment banks in private and public financings. He has also acted as lead counsel on over 100 mergers and acquisitions valued at more than $50 billion.

Mr. Davidson has spoken on corporate governance issues at the Stanford Directors College, lectured on venture capital investments at the Stanford Law School, the Stanford Business School and the Haas Business School, taught courses on Deals and Mergers & Acquisitions at Stanford Law School, and chaired the Practising Law Institute programs on Private Placements and Mergers & Acquisitions of High Technology Companies. He has also served on the boards of directors of non-profit organizations, including the Children’s Health Council and Pacific Community Ventures.

Mr. Davidson is a member of the State Bar of California. He graduated Phi Beta Kappa from Stanford University in 1970 with a B.S. in electrical engineering and received an M.S. in computer systems from Stanford in 1971. He graduated from Stanford Law School in 1974 and was a member of the Order of the Coif. Prior to and during law school, Mr. Davidson worked as a computer systems engineer at Stanford Research Institute and at Measurex Corporation. Following law school, he was a law clerk for Judge Ben C. Duniway in the United States Ninth Circuit Court of Appeals in San Francisco.

Paulette has been with KPMG for 19 years and a partner since 2001. She is a graduate of KPMG’s exclusive Lead Partner Academy, a member of the 2008 KPMG Partner Council, and is also an accredited International Financial Reporting Standards (IFRS) reviewing partner. Paulette has over 16 years of experience in the life sciences industry, where she has served biotechnology, pharmaceutical, and medical device companies providing accurate and timely financial reporting to investors and the SEC. Her experience includes Initial Public Offerings, business combinations, analysis of complex collaboration arrangements for revenue and cost capitalization implications. Her client base includes start-ups, small and middle market privately held companies, as well as serving as the audit partner for U.S. and International publicly held corporations. Paulette is the author of several thought leadership publications and is a contributing author to the biotechnology volume of KPMG’s global risk and disclosures handbook. Paulette is a member of the boards of directors of BayBio, the Bay Area biotechnology trade organization, and WEALTH Women - women executives advancing life sciences, technology and healthcare - and serves as a judge for the World Economic Forum’s Technology Pioneers Award. Paulette is a summa cum laude graduate of California State University and is a member of the American Institute of Certified Public Accountants and a California CPA.

Keith serves as Deloitte’s National Life Science sector Leader. He has over 30 years of experience serving a variety of Life Science and Health care clientele ranging from early-stage venture-backed companies to Fortune 500 companies. He serves clients in the Bay area and across the country in both a consulting as well as audit capacity. He has broad experience in Security and Exchange Commission, biotech, health care and pharmaceutical industry regulatory, accounting and financial reporting requirements. He has extensive experience in dealing with the Sarbanes-Oxley Act in addition to a deep knowledge of SEC, GAAP, GAAS, IAS and PCAOB matters, Keith has strong experience in the areas of mergers & acquisitions, dispositions, due diligence, and pharmaceutical and biotech industry matters such as partnering arrangements, joint ventures and pharmaceutical rebates. Keith is a Board member and past Board Chair of the Bay Area chapter of the American Heart Association.

Mr. Dossa is a Vice President for VWR International, LLC and is responsible for Northern California and Northwest Markets as well as VWR’s Western US Direct Channel. He is based out of VWR’s Regional Distribution Center in Brisbane, CA.

He assumed the leadership responsibilities for VWR’s business activities in these markets in 2004. The bay area has the highest concentration of business and field personnel for VWR which he oversees.

His team is responsible for developing, servicing, and growing of all VWR’s core market segments served – Pharmaceutical, Biotech, Life Science, Medical Device, Cleantech, Environmental, Education, Food Processing, and Technology.

He has been in the scientific supplies and distribution business for over 23 years. He started with American Scientific Products which became Baxter SP and then subsequently VWR International, LLC. He has held numerous management and leadership positions over the last 18 years and has been a Vice President since 2000 leading several strategic business units.

He serves on the Board at BayBio and is actively involved in many other Bay Area Professional Associations including The Institute for Supply Chain Management, SEMI, and PDA.

He has a BA in Finance from Washington State University. He has attended many leadership, management, and specialized skills workshops and or training seminars over the last 23 years.

With more than 25 years of executive leadership and biotechnology and pharmaceutical industry experience, his expertise spans the areas of therapeutic products, operations and corporate development. Steve Engle was chief executive officer of XOMA, Inc. until 2011. Prior to that he served as chairman of the board and chief executive officer of La Jolla Pharmaceutical Company, a publicly-held biopharmaceutical company focused on the research and development of therapeutic products for autoimmune and antibody-mediated diseases. He joined La Jolla Pharmaceutical Company in 1993, became president and a director in 1994, CEO in 1995, and chairman of the board in 1997. Prior to joining La Jolla, he held executive-level positions at Cygnus Therapeutic Systems, a developer of drug delivery systems, and Micro Power Systems, Inc., a manufacturer of high technology products, including medical devices. He began his professional career with the Strategic Decisions Group and the Stanford Research Institute. Mr. Engle is a graduate of the University of Texas with B.S. and M.S. degrees in biomedical engineering.

Matthew K. Fust joined Onyx in January 2009 as executive vice president and chief financial officer. Mr. Fust is responsible for key functions including financial planning and analysis, accounting, tax and SEC reporting, as well as information technology, facilities and purchasing. Prior to joining Onyx, Mr. Fust was executive vice president and chief financial officer at Jazz Pharmaceuticals, which he joined in 2003. From 2002 until 2003, he was chief financial officer at Perlegen Sciences, a biotechnology company. Previously, he was senior vice president and chief financial officer at ALZA Corporation where he was an executive from 1996 until 2002. From 1991 until 1996, Mr. Fust was a manager in the healthcare strategy practice at Anderson Consulting. Mr. Fust earned an undergraduate degree in accounting from the University of Minnesota and an MBA from Stanford University. He serves as a member of the board of directors for Sunesis Pharmaceuticals.

Corey Goodman, Ph.D., is Managing Director and co-founder of venBio LLC, Adjunct Professor at the University of California, San Francisco, and Chair of the Board of Directors of Limerick BioPharma, iPierian, PhyloTech, and Oligasis, Vice Chair of the Supervisory Board of Evotec, and member of the Board of NeuroTherapeutics Pharma and Mirna Therapeutics.

Corey received his B.S. from Stanford University, Ph.D. from U.C. Berkeley, and was a postdoctoral fellow at U.C. San Diego. He spent over two decades as a professor of biology and neuroscience at Stanford and U.C. Berkeley. He won numerous scientific awards (e.g., Alan T. Waterman Award from the National Science Board, Gairdner International Award for Achievement in Medical Sciences, March-of-Dimes Prize in Developmental Biology), was a Howard Hughes Medical Institute Investigator, Evan Rauch Chair of Neuroscience, and co-founded the Wills Neuroscience Institute.

Corey was elected a member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the American Philosophical Society.

He is co-founder of three biotechnology companies – Exelixis, Renovis, and PhyloTech -- and served as CEO of Renovis prior to its acquisition by Evotec.

Corey spent two years as President of Pfizer’s Biotherapeutics and Bioinnovation Center (BBC), and a member of Pfizer’s Executive Leadership Team.

Corey is a member of the California Council on Science and Technology, the Board of the Pacific Institute, McKnight Endowment Fund for Neuroscience, BayBio, Biotechnology Institute, Bay Area Science and Innovation Consortium, QB3 (UCSF-UCB-UCSC) Industry Advisory Board, Stanford’s BioX Biosciences Advisory Council, Spinal Muscular Atrophy Foundation, Stanley Center for Psychiatric Research (of Harvard and MIT), and is former Chair of the National Research Council's Board on Life Sciences. He is also on the Editorial/Advisory Board of the journals Science Translational Medicine and Neuron.

He and his wife Marcia Barinaga oversee the Barinaga Ranch and farmsted sheep dairy in West Marin, California, where Marcia produces artisanal sheep cheese.

Hoyoung Huh, M.D., Ph.D. is currently President and Chief Executive Officer of BiPar Sciences, an oncology drug development company focused in novel DNA repair inhibitors for breast, ovarian and brain cancers, located in Northern California. BiPar Sciences recently announced a merger with sanofi-aventis for $500 million and will remain as a wholly-owned subsidiary.

Prior to joining BiPar, Dr. Huh served as Chief Operating Officer and Head of the PEGylation Business Unit at Nektar Therapeutics, a drug development company in the therapeutic areas of oncology, CNS/pain, diabetes and infectious diseases. At Nektar, Dr. Huh led significant, revenue-generating partnerships with major pharmaceutical companies, including Amgen Inc., Bayer AG, Baxter International Inc., Bristol-Myers Squibb Co., Novartis AG, and Roche Holding Ltd.

Prior to Nektar, Dr. Huh was a Partner at McKinsey and Company, where he focused primarily in the biopharmaceutical sector in the United States, Europe and Asia with areas of expertise in licensing, mergers and acquisitions and innovative product launches.

As an industry thought leader, Dr. Huh speaks frequently about licensing, mergers and acquisitions, innovative product development and commercialization strategies. He currently serves on the Board of Directors at BayBio (a biotechnology industry association), Nektar Therapeutics (public biotech), SciDose (private biotech), and Interplast (medical non-profit).

Dr. Huh holds an M.D. from Cornell University, a Ph.D. in Genetics/Cell Biology from the Cornell University/Sloan-Kettering Institute, and a bachelor’s degree in biochemistry from Dartmouth College.

Perry Karsen brings over 25 years of pharmaceutical and biopharmaceutical industry experience to Pearl. He joined from Celgene Corporation where he was most recently Regional President, Asia/Pacific and Head of Worldwide Business Development. At Celgene, he was directly responsible for emerging businesses in the Asia/Pacific Region as well as all licensing and strategic collaboration initiatives. In addition, he was a member of the Management, Operating and Product Development Committees. Previously, he was Senior Vice President, Business Development at Human Genome Sciences.

Earlier in his career, he held positions including Vice President, Strategic Business Analysis and Development, Bristol-Myers Squibb; Senior Vice President Marketing and Sales, Zimmer, Inc.; Director, Business Development and Representative Director, Japan, at Genentech and various domestic and international roles with Abbott. Additionally, he was a General Partner at Pequot Ventures responsible for early and late stage investments in biotechnology and medical devices.

Perry serves as a member of the Board of Directors of the Biotechnology Industry Organization (BIO) and as a member of the Board of Directors of BayBio. Perry has a Masters of Management degree from Northwestern University’s Kellogg Graduate School of Management, a Masters in Teaching of Biology from Duke University, and a B.S. in Biological Sciences from the University of Illinois, Urbana.
 

David W. Martin, Jr., M.D., is Chairman and Chief Executive Officer of Avid Biotics. Previously, Dr. Martin was Chairman and CEO of GangaGen, Inc., and he was a founder and CEO of Eos Biotechnology, which merged with Protein Design Labs in April 2003. Previously he has been SVP of R&D at Genentech (1982-1990), Executive VP of R&D at DuPont Merck (1991-1993), and President of Chiron Therapeutics (1994-1995). He currently serves as lead director of the Boards of Varian Medical Systems, Inc., Palo Alto, and Cubist Pharmaceuticals, Inc., Lexington, MA, and he is a member of the California Counsel on Science and Technology and vice-chairman of BayBio. Prior to joining Genentech in 1982, he was Professor of Medicine and Biochemistry at UCSF and Investigator, Howard Hughes Medical Institute.

Alan Mendelson is a partner in the firm’s Silicon Valley office and the Co-Chair of the firm’s Venture and Technology Group. He joined the firm in May 2000, bringing a wealth of practice and management experience in the areas of corporate and securities law.

Mr. Mendelson's practice is primarily targeted toward the representation of emerging and public growth companies, with strong emphasis on companies in the life sciences industry. He has handled and supervised a variety of major business transactions, including venture capital financings on behalf of companies and investors, private placements and public offerings on behalf of companies and leading investment banking firms, mergers and acquisitions, joint ventures and other strategic collaborations, R&D limited partnerships and commercial transactions.

Mr. Mendelson is a member of the Emerging Companies Section Governing Body of the Biotechnology Industry Organization (BIO), 2004. He serves as the corporate secretary for many public and private companies and currently serves on the board of directors of Connectix Corporation, QLT, Inc. and Valentis, Inc. From November 1995 through June 1996, he served as acting General Counsel of Cadence Design Systems Inc., a leading EDA software and services company. Previously he served as secretary and acting general counsel of Amgen Inc., a leading biopharmaceuticals company. From 1991 through 1994, Mr. Mendelson served as the President of the Board of Directors of the National Kidney Foundation of Northern California Inc. and is currently a member of the Major Gifts Council for the Foundation for Lucile Packard Children’s Health. From 1995 to 1998, he served as a member of the Board of Visitors of the College of Medicine at the University of California, Irvine.

Mr. Mendelson has spoken on topics related to strategic alliances, financing strategies and clinical and regulatory disclosure issues before the Licensing Executives Society, the Association of Bioscience Financial Officers, CLE International, the Biotechnology Industry Organization and the University of California, Berkeley.

Since 1993, Mr. Mendelson has been listed in editions of "The Best Lawyers in America." He was recognized as one of America’s 100 most influential lawyers in the 1994, 1997 and 2000 editions of the National Law Journal and as one of “California’s 100 Most Influential Lawyers” in 1998 and 1999 editions of California Law Business.

Phil served as Chief Financial Officer and Vice President, Finance and Operations of Peplin, Inc. an Australian listed company.  Previously, Phil served as vice president, Finance and Operations at Chiron Corporation, a biotechnology company acquired by Novartis AG in 2006.  Chiron's Biopharmaceuticals business employed approximately 2,200 people and recorded revenue of $800 million and had a portfolio of R & D expenses of $300 million in 200.  From 1995 to his departure in April 206, Mr. Moody held positions of increasing seniority at Chiron, including Vice President of Finance and Chief Accounting Officer.  While in  Biopharmaceuticals, Phil was responsible for all financial aspects of the business, and during his tenure he managed many other activities including collaboration management, manufacturing and process development, marketing and sales.  Phil has extensive experience as an executive in multiple industries, having been at IBM and ROLM in executive capacities and consulted with other companies, both public and private.  His expertise includes:

Executive Leadership

Strategic Planning

Investor Relations and Capital Markets

International Finance

Supply Chain

Information Technology

Organizational Development

Jeffrey N. Peterson, CEO for Target Discovery, Inc., brings broad executive general management, multi-functional, multi-business and international experience to Target Discovery. His diverse cross-functional experience includes roles in general management, strategic planning, business development, technology licensing, marketing/sales, operations/quality and R&D. Following an 11 year career in General Electric's Engineered Materials and Plastics businesses, he spent 9 years in key management roles in Abbott Laboratories' Diagnostics and International (Pharmaceuticals, Hospital Products, Nutritionals, Consumer) businesses. Most recently he served as CEO and General Manager of Abbott South Africa, doubling the sales and tripling the income of this 50 year-old business in 3.5 years, during the tumult of South Africa's political transition. He played an earlier pivotal management role in Abbott's successful introduction and support of multiple new diagnostics instrument and reagent systems in the history-making X-System series, including the IMx (the highest global sales diagnostic system in history). While in South Africa, Mr. Peterson also served as Chairman of the Board of the American International School of Johannesburg. Mr. Peterson holds BSChE and MSChE (Chemical Engineering) degrees from MIT.

Kim Popovits has served as President and Chief Executive Officer of Genomic Health, Inc. since January 2009 and as President and Chief Operating Officer since January 2002. From November 1987 to February 2002, Kim served in various roles at Genentech, Inc., a biotechnology company, most recently as Senior Vice President, Marketing and Sales from February 2001 to February 2002, and as Vice President, Sales from October 1994 to February 2001. Prior to joining Genentech in November 1987, she served as Division Manager for American Critical Care, a Division of American Hospital Supply. Kim holds a Bachelor of Arts degree in Business from Michigan State University.

Mike has been Chief Executive Officer and Chairman of Ardelyx since March 2009. Before Ardelyx, Mike was a partner at New Enterprise Associates (NEA) one of the world’s largest and most successful venture capital firms and specialized in healthcare investments focusing on the biotechnology and pharmaceutical sectors.

Prior to joining NEA in 2002, Mike spent 15 years in commercial and operating leadership roles in the biotech and pharmaceutical industries. He was Senior Vice President, Therapeutics and General Manager of the Renal Division at Genzyme Corporation.  He built the Latin American division for Genzyme and was also Senior Product Manager for Genzyme’s $1+ billion therapies for Gaucher Disease, Ceredase and Cerezyme, and was instrumental in the worldwide launch of both products. Mike also spent two years with Genzyme’s Diagnostic products and services division. 

Previous to Genzyme, Mike held business development and sales and marketing positions at Repligen and Bristol-Myers.

Mike received his B.A. from DePauw University.

A. Franklin Rice, MBA, has held positions of increasing responsibility within the biotechnology industry since 1984. During this time frame he has successfully raised significant money through corporate development transactions involving strategic alliances, technology licenses, funded research, contract manufacturing and off-balance sheet leasing. Frank was one of the first employees at Genencor International where in his role as Director of Business Development he was instrumental in establishing the initial commercial and operational success of that company. More recently as VP of Biotechnology and Pharmaceuticals for Bechtel Group he has gained significant experience in global sales and marketing to the PhRMA companies. Combined with degrees from Clarkson, Rochester and MIT, Frank's experience in business development and operations from the ground up represents a significant addition to VistaGen's management team.

Steve is a Senior Vice President, responsible for Alexandria's San Francisco Bay Area office/laboratory real estate portfolio including the Alexandria Center for Science and Technology at Mission Bay. He has led the growth of the region for nearly 10 years, from an existing asset base of 500,000 square feet to approximately 2.2 million square feet and a development pipeline of 3.2+ million square feet. Steve has 26 years of experience in the commercial real estate and high technology industries, negotiating complex transactions with a value in excess of $1 billion. He is a graduate of Santa Clara University's graduate business program and Claremont McKenna College.

Howard Robin joined Nektar Therapeutics in January 2007. He has more than 25 years of successful biopharmaceutical experience managing clinical development and commercial operations. Most recently, Mr. Robin served as President and Chief Executive Officer of Sirna Therapeutics, a clinical-stage biotechnology company pioneering RNAi-based therapies for serious diseases and conditions, including age-related macular degeneration (AMD), hepatitis C, asthma, respiratory syncytial virus (RSV) and Huntington's disease. During his tenure at Sirna, Mr. Robin successfully re-launched the company and created significant shareholder value that led to its acquisition by Merck for $1.1 billion.

Prior to Sirna, Mr. Robin spent 20 years at Berlex Laboratories, the U.S. pharmaceutical subsidiary of the German pharmaceutical firm Schering AG. From 1991 to 2001, he served as corporate vice president and general manager of their U.S. Therapeutics division and was responsible for the development of drugs, such as Betaseron® (Interferon beta-1b) for multiple sclerosis and Fludara® (fludarabine phosphate) for chronic lymphocytic leukemia, generating annual global sales in excess of $800 million. He also served as a member of the Executive Committee. Prior to that, he was vice president of Finance and Business Development and CFO of Berlex. Earlier in his career, Mr. Robin was a senior associate with Arthur Andersen and Co.

Mr. Robin holds a B.S. in Accounting and Finance from Fairleigh Dickinson University in New Jersey.

Terry Rosen, Vice President, leads bTherapeutic Discovery department and is the site head for Amgen South San Francisco.  A seasoned executive, Rosen has more than 25 years of experience in the biotechnology and pharmaceutical industries.  Rosen joined Amgen with the acquisition of Tularik in 2004 and was named Amgen Washington site head in 2006.  He transitioned to his leadership role heading Chemistry Research and Discovery in 2007 and became the head of Protein Sciences in 2011.  Prior to joining Amgen, Rosen held several executive positions at Tularik including executive vice president, Operations, vice president, Research Operations, and vice president, Medicinal Chemistry.  Rosen has also held scientific and management positions at Pfizer and Abbott Laboratories.  Rosen serves on the leadership committee of the University of Michigan Undergraduate Research Opportunity Program, the University of California, Berkeley Chemistry Advisory Board and is a member of the Board of Trustees of Lick-Wilmerding High School in San Francisco.

Rosen received his Bachelor of Science in Chemistry from the University of Michigan, Ann Arbor and earned his Doctorate in Organic Chemistry from the University of California, Berkeley.  He holds numerous patents and has published extensively in the areas of medicinal and synthetic organic chemistry.

Glen Y. Sato is a partner in the Life Sciences and Securities Regulation practice groups and a member of Cooley's Business department. He rejoined the Firm in 2006 and is resident in the Palo Alto office.

Mr. Sato's practice focuses on corporate transactions, SEC reporting and compliance, disclosure issues, intellectual property licensing and licensing strategy, general corporate counseling, insider trading compliance and working with Boards of Directors and audit committees on various risk and accounting related matters. Together with strong finance capabilities, Sato also has substantial experience in corporate partnering, international and domestic M&A and other heavily negotiated transactions. He has worked closely with underwriters on public and private company acquisitions and led successful initial public, follow-on and secondary, and convertible note offerings. He has also led or been significantly involved in corporate partnering and licensing transactions involving leading pharmaceutical and biotechnology companies such as Abbott, Bayer, Biogen Idec, Bristol-Myers Squibb, Exelixis, Eli Lilly, Genentech, GlaxoSmithKline, MedImmune, PDL BioPharma, Progenics, Roche, Sankyo and Tanox.

Prior to joining the Firm, Mr. Sato served in diverse legal, financial, operational and strategic planning positions where his responsibilities included finance, business development, IS, HR, and Facilities. He most recently served as Protein Design Labs' (PDL) Senior Vice President and Chief Financial Officer. He joined PDL from Exelixis, Inc., where he served as SVP, Chief Financial Officer and General Counsel for approximately three years. Prior to his time at Exelixis, he served in various legal and strategic planning positions at PDL, including Vice President, Legal and General Counsel. In addition, Mr. Sato worked at NeXT Computer, Inc. as Associate General Counsel. He was an attorney in Cooley's Business Department in Palo Alto for two years. Mr. Sato started his career at Jones, Day in Washington, DC.

Mr. Sato received his JD and MBA from UCLA in 1987, where he was an Associate Editor of the Law Review. He received a Bachelor's degree in Economics and the College of Social Studies in 1981 from Wesleyan University.

Mr. Sato is a member of the State Bar of California and an inactive member of the Washington, DC Bar Association.

Renee Tannenbaum is President of Myrtle Potter & Company, LLC, a life science and healthcare consulting firm whose clients include for-profit and non-profit corporations and boards of directors, focusing on business strategy, licensing, acquisition, product development and commercialization. Prior to joining Myrtle Potter & Company, LLC, Renee was Executive Vice President and Chief Commercial Officer at Elan Pharmaceutics, Inc. from 2009 to 2011, where she was responsible for revenue generation for Elan’s marketed products, most notably Tysabri, preparing for the commercialization of the company’s pipeline, including its Alzheimer’s portfolio; and strengthening the company’s overall commercial capabilities. 

Prior to her role at Elan, Dr. Tannenbaum was at Novartis Pharma Ag for 3 years, where she led the Global Commercial Operations organization, with responsibility for Marketing Sciences, Global Sales, Marketing Excellence, Marketing and Sales Learning, Sales and Marketing Services and Congresses and Conventions.  Prior to that, Renee spent 9 years at Bristol Myers Squibb and 16 years at Merck and Company where she held a variety of leadership positions in operations and general management. She has a proven track record of success in leading high performing businesses and developing and implementing innovative commercial strategies; expertise in creating new commercial capabilities to drive growth strategies; significant expertise in product launches, sales, marketing, product development, alliance management, product commercialization and leadership development.

Prior to joining the industry, Renee was an Assistant Professor of Clinical Pharmacy at the Philadelphia College of Pharmacy and Sciences, now known as the University of the Sciences at Philadelphia. She retains a Clinical Associate Professor position at the University.

Renee received her Doctor of Pharmacy degree from the Philadelphia College of Pharmacy and Sciences, an MBA from Temple University, and her Bachelors of Science degree in Pharmacy from the University of Connecticut.  She serves on the Board of the Women Business Leaders in Healthcare (WBL) and is a member of the Healthcare  Businesswomen’s Association (HBA). She also serves on the Advisory Board for the HBA and HBA Europe and Bay Area HBA. Renee received the University of Connecticut Distinguished Alumni Award in 2006.

Stephen Thau is a partner in Morrison & Foerster's Palo Alto office and former co-chair of the firm's Life Sciences Group. His practice focuses on the representation of life science, medical device, and other technology companies at all stages of their life cycles, from company formation, equity and debt financing, merger and acquisition transactions, to strategic alliances and public offerings. He also represents venture capital and investment banking firms in public and private financing transactions. He has represented companies and investors in more than one hundred venture capital and debt financing transactions, as well as in numerous public offerings and public and private M&A transactions. In 2008, Mr. Thau re-joined Morrison & Foerster after having practiced corporate law for ten years at Venture Law Group and Heller Ehrman LLP. He began his legal practice as a patent and securities litigator at Morrison & Foerster and served as a law clerk to the Hon. Vaughn R. Walker in the United States District Court in the Northern District of California. Mr. Thau earned his J.D. from Stanford University, where he was elected to the Order of the Coif and was managing editor of the Stanford Law Review. He earned his A.B. in Biology from Harvard University, magna cum laude.

William D. Young is currently a Venture Partner at Clarus Ventures in South San Francisco, CA. He is the former Chairman of the Board and Chief Executive Officer of Monogram Biosciences a pioneer in developing and marketing products for personalized medicine. Monogram was acquired by LabCorp in August of 2009. He served as Chief Executive Officer from November 1999 and as the Chairman of the Board from May 1999. From March 1997 to October 1999, Mr. Young was Chief Operating Officer of Genentech, Inc., the worlds most successful biotechnology company. As COO at Genentech, Mr. Young was responsible for all of the company's development, operations and commercial functions. Mr. Young joined Genentech in 1980 as Director of Manufacturing and Process Sciences and held various executive positions prior to becoming COO. Prior to joining Genentech, Mr. Young was employed by Eli Lilly and Company for 14 years. Mr. Young is Chairman of the Board of Directors of Biogen IDEC, Inc., a member of the Board of Theravance, Inc and Executive Chairman of NanoString, a private company based in Seattle, as well as a former chairman and current member of the board of BayBio. He received his bachelor's degree in chemical engineering from Purdue University, his MBA from Indiana University and an honorary doctorate in engineering from Purdue University. In 1993 he was elected to the National Academy of Engineering for his contributions to Biotechnology.